Eagle Pharmaceuticals Reports First Quarter 2023 Results
May 09, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and...
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS
May 01, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) --...
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023
April 27, 2023 16:30 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023...
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)
April 05, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr....
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
March 13, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million,...
Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference
March 09, 2023 16:10 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
March 03, 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and...
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023
January 10, 2023 14:00 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: ...
Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022 16:30 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy
December 19, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth...